From Guideline to Practice: Bridging the 3 Gaps in OAB

Even the most rigorously developed clinical guideline is only as effective as the degree to which it penetrates daily practice, and the 2024 AUA/SUFU overactive bladder (OAB) guideline—built from a comprehensive systematic review rather than an incremental update—faces meaningful implementation gaps in the real world. In the final segment of this series, Aleece Fosnight, MSPAS, PA-C, CSC-S, CSE, IF, MSCP, HAES founder, Fosnight Center for Sexual Health in Asheville, North Carolina, identifies 3 gaps she considers most consequential: clinician awareness, prescribing mindset, and payer alignment. On awareness, she notes that many clinicians are not yet familiar with the scope of the guideline's changes, and that reading the document is only the first step—translating its principles into concrete changes in practice workflow requires deliberate action that has not yet occurred at scale.

The mindset gap, Fosnight argues, is the deeper and more personal challenge. Shared decision-making has been a stated value in medicine for years, yet the patient is often conspicuously absent from the clinical encounter in which treatment decisions are made. Generations of clinicians have been trained to direct rather than partner, and the reflex toward a step-by-step, protocol-driven approach to OAB does not dissolve simply because a new document has been published. She describes the 2024 guideline's formalization of shared decision-making—placing it in explicit, central terms alongside strong clinical evidence—as a meaningful structural lever for changing how those clinical conversations unfold, but acknowledges that the cultural shift required of individual practitioners is not immediate.

The insurance gap, Fosnight states plainly, is the most operationally disruptive of the three: payers have not aligned their prior authorization requirements with the 2024 guideline, and continue to demand documentation of failed behavioral therapy and oral medications before approving minimally invasive options—exactly the step-therapy mandate the guideline has moved away from. This mismatch places clinicians in the position of navigating coverage requirements that diverge from evidence-based best practice, particularly in cases where proceeding directly to a minimally invasive therapy would be the most appropriate and patient-centered choice. Fosnight's closing message to clinicians is direct: the most important takeaway from this program is to present patients with the full range of available options—from bladder training to botulinum toxin—in plain and honest terms, and then yield the decision to the patient. The clinician's role, she concludes, is to guide and translate, not to choose.